Welcome to our dedicated page for Talis Biomedical news (Ticker: TLIS), a resource for investors and traders seeking the latest updates and insights on Talis Biomedical stock.
Talis Biomedical Corporation (Nasdaq: TLIS) delivers innovative molecular diagnostics through its Talis One® System, enabling rapid point-of-care testing for infectious diseases. This dedicated news hub provides investors and healthcare professionals with essential updates on financial developments, regulatory milestones, and technological advancements.
Access timely updates on strategic initiatives including Nasdaq compliance efforts, product pipeline expansions, and financial restructuring. Track announcements about the Talis One® System's evolving test panels and operational efficiency improvements demonstrated through recent cost-saving measures.
Key content categories include earnings reports, leadership updates, regulatory filings, and clinical study results. Stay informed about developments in women's health diagnostics and corporate actions like the completed 1-for-15 reverse stock split designed to maintain Nasdaq listing compliance.
Bookmark this page for consolidated access to press releases about assay validations, partnership opportunities, and financial strategy updates. Check regularly for new information about Talis Biomedical's progress in transforming point-of-care diagnostics while maintaining fiscal responsibility.
Talis Biomedical Corporation (Nasdaq: TLIS) reported its financial results for Q4 and the full year of 2022, showing a revenue of $0.3 million in Q4, down from $0.9 million in Q4 2021. The company experienced a net loss of $26.9 million for Q4 2022, an improvement over the $28.7 million loss in Q4 2021. For the full year, total revenue declined to $1.2 million from $8.2 million, primarily due to the completion of a grant contract. Operating expenses decreased from $200 million in 2021 to $120 million in 2022. Talis has extended its cash runway into 2025, currently holding $130.2 million in cash.
Talis Biomedical Corporation (Nasdaq: TLIS) reported its financial results for Q3 2022, showing significant revenue growth to $0.8 million from $0.2 million in Q3 2021, fueled by antigen testing sales. Despite this, operating expenses decreased to $26.3 million from $38.6 million in the prior year, leading to a net loss of $26.0 million, improved from a loss of $38.4 million. The company is refocusing its strategy on Women's and Sexual Health markets, implementing a 35% workforce reduction to lower expenses and aiming to reduce cash burn, with $143.8 million in cash reserves as of September 30, 2022.
Talis Biomedical Corporation (Nasdaq: TLIS) reported its Q2 2022 financial results and business updates on August 2, 2022. The company achieved $0.6 million in revenue, a notable increase from $0.1 million in Q2 2021, with $0.5 million from product sales. Operating expenses reduced significantly to $26.5 million from $64.5 million year-over-year, contributing to a net loss decrease to $27 million. Talis announced a strategic shift away from stand-alone COVID-19 testing to focus on women’s health, specifically a multiplex panel for Chlamydia and Gonorrhea. The company maintains $165 million in cash to support this new direction.
Talis Biomedical Corporation (Nasdaq: TLIS) announced its first quarter 2022 financial results, reporting revenues of $3.2 million, down from $7.0 million in Q1 2021. The decline includes $2.3 million in product revenue from antigen testing and $0.9 million in grant revenue. Operating expenses decreased to $32.6 million from $67.5 million, leading to a net loss of $33.1 million, less than the $60.5 million loss in the previous year. Talis remains focused on cash preservation, with $187.6 million in cash as of March 31, 2022.
Talis Biomedical Corporation (TLIS) has announced that it will report its first quarter financial results on May 10, 2022, after market close. The company will host a conference call at 1:30 PM PT (4:30 PM ET) to discuss these results. Interested parties can join via telephone or watch the webcast on their investor website. Talis is focused on improving health equity through accurate infectious disease testing, particularly with its Talis One system, which has received Emergency Use Authorization from the FDA for COVID-19 testing.
Talis Biomedical Corporation (Nasdaq: TLIS) reported its fourth quarter and full-year 2021 financial results, showing grant revenue of $0.9 million for Q4 2021 versus $0.2 million in Q4 2020. The company incurred a net loss of $28.7 million in Q4 2021, an improvement from $44.2 million in the prior year. Total operating expenses for 2021 reached $200 million, up from $102.1 million in 2020, largely due to investments in manufacturing scale-up. Talis has postponed the launch of the Talis One™ COVID-19 Test System due to manufacturing challenges while reducing its workforce by 25% to save costs.
Talis Biomedical Corporation (TLIS) announced its plans to report fourth quarter and full year 2021 financial results on March 15, 2022, after market close. A conference call will follow at 1:30 p.m. PT (4:30 p.m. ET) for interested stakeholders. The company is focused on advancing health equity through accurate infectious disease testing, deploying its Talis One system for rapid molecular testing. The Talis One COVID-19 Test System has received Emergency Use Authorization from the FDA for multiple healthcare settings.
Talis Biomedical Corporation (Nasdaq: TLIS) has announced the promotion of Rob Kelley to Chief Executive Officer and Director, effective immediately. He replaces Brian Blaser, who has stepped down due to personal matters. Kelley, previously the Chief Commercial Officer, has over 25 years of experience in biotechnology and has held significant roles at companies such as Genalyte and Illumina. Talis focuses on developing accurate infectious disease testing, having received Emergency Use Authorization for its Talis One COVID-19 Test System.
Talis Biomedical Corporation (TLIS) has granted an inducement award to its new CEO, Brian Blaser, as part of the company's 2021 Inducement Plan, complying with Nasdaq rules. The award consists of stock options for 638,144 shares and restricted stock units for 625,000 shares of common stock. Both awards will vest over five years, with an initial 20% vesting after one year. Talis focuses on improving health equity through accurate infectious disease testing, having received Emergency Use Authorization from the FDA for its Talis One COVID-19 Test System.
Talis Biomedical Corporation (Nasdaq: TLIS) reported its third quarter 2021 results, highlighting significant progress with the FDA's Emergency Use Authorization for the Talis One COVID-19 Test System. The product demonstrated 100% concordance in clinical studies, including for the Delta variant. Q3 grant revenue was $0.2 million, a drop from $9.5 million in Q3 2020, while operating expenses were relatively stable at $38.6 million. The net loss increased to $38.4 million compared to $29.5 million in the previous year. Cash reserves stood at $273.6 million as of September 30, 2021.
